318 related articles for article (PubMed ID: 16598306)
1. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
2. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Mesa RA; Tefferi A; Lasho TS; Loegering D; McClure RF; Powell HL; Dai NT; Steensma DP; Kaufmann SH
Leukemia; 2006 Oct; 20(10):1800-8. PubMed ID: 16871275
[TBL] [Abstract][Full Text] [Related]
4. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
Grandage VL; Everington T; Linch DC; Khwaja A
Br J Haematol; 2006 Nov; 135(3):303-16. PubMed ID: 16956345
[TBL] [Abstract][Full Text] [Related]
5. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Jelinek J; Oki Y; Gharibyan V; Bueso-Ramos C; Prchal JT; Verstovsek S; Beran M; Estey E; Kantarjian HM; Issa JP
Blood; 2005 Nov; 106(10):3370-3. PubMed ID: 16037387
[TBL] [Abstract][Full Text] [Related]
6. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia.
Forbes LV; Gale RE; Pizzey A; Pouwels K; Nathwani A; Linch DC
Oncogene; 2002 Sep; 21(39):5981-9. PubMed ID: 12203110
[TBL] [Abstract][Full Text] [Related]
7. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
8. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
[TBL] [Abstract][Full Text] [Related]
9. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Levine RL; Loriaux M; Huntly BJ; Loh ML; Beran M; Stoffregen E; Berger R; Clark JJ; Willis SG; Nguyen KT; Flores NJ; Estey E; Gattermann N; Armstrong S; Look AT; Griffin JD; Bernard OA; Heinrich MC; Gilliland DG; Druker B; Deininger MW
Blood; 2005 Nov; 106(10):3377-9. PubMed ID: 16081687
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of STAT transcription factors in acute myelogenous leukemia.
Spiekermann K; Biethahn S; Wilde S; Hiddemann W; Alves F
Eur J Haematol; 2001 Aug; 67(2):63-71. PubMed ID: 11722592
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
13. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; Shimada K; Morishita Y; Kinoshita T; Naoe T
Leukemia; 2006 Jun; 20(6):1168-9. PubMed ID: 16557239
[No Abstract] [Full Text] [Related]
14. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
18. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.
Fröhling S; Lipka DB; Kayser S; Scholl C; Schlenk RF; Döhner H; Gilliland DG; Levine RL; Döhner K
Blood; 2006 Feb; 107(3):1242-3. PubMed ID: 16434499
[No Abstract] [Full Text] [Related]
19. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Haan S; Wüller S; Kaczor J; Rolvering C; Nöcker T; Behrmann I; Haan C
Oncogene; 2009 Aug; 28(34):3069-80. PubMed ID: 19543316
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
Nelson ME; Steensma DP
Leuk Lymphoma; 2006 Feb; 47(2):177-94. PubMed ID: 16321848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]